Sponsor

2015/12/01

Nature Reviews Drug Discovery contents December 2015 Volume 14 Number 12 pp 805-877

If you are unable to see the message below, click here to view.

Nature Reviews Drug Discovery


Advertisement
 
Nature Reviews Drug Discovery
Special on targeting the IL-17 pathway in inflammatory disease
 
Animation and Poster produced with support from
 
 
TABLE OF CONTENTS
 
December 2015 Volume 14 Number 12Advertisement
Nature Reviews Drug Discovery cover
Impact Factor 41.908 *
In this issue
Comment
News and Analysis
Research Highlights
Perspectives
Reviews

Also this month
 Featured article:
Complement, a target for therapy in inflammatory and degenerative diseases
B. Paul Morgan & Claire L. Harris

The discussion on Alzheimer’s Disease continues 

Nature Neuroscience presents a community forum on Alzheimer's Disease (AD) research. ACCESS NOW to view videos of our panel event at SfN 2015, read related articles for free, and discuss critical issues facing AD research today.

Produced with support from
Eli Lilly and Company and vTv Therapeutics

Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
 
Advertisement

BIOPHARMA DEALMAKERS
BioPharma DealmakersCompany Profiles and Partnering Opportunities

 
Advertisement
Focus on Telomeres

In this special Focus on Telomeres, Nature Structural & Molecular Biology explores how the length of chromosome ends is regulated to limit cell proliferation, and how this mechanism is compromised in human disease or is circumvented by tumor cells, thus permitting unregulated cell growth. 

Access the Focus free online.

Produced with support from Geron Corporation and Janssen Oncology.
 
Comment: Industry-academia collaborations for biomarkers
Khusru Asadullah, Andreas Busch, Matthias Gottwald, Petra Reinke & Lilla Landeck
p805 | doi:10.1038/nrd4727
Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success.
Abstract | Full Text | PDF | Supplementary information

 
NEWS AND ANALYSIS
Top
The phenotypic screening pendulum swings
Asher Mullard
p807 | doi:10.1038/nrd4783
Industry and academic scientists are working together to figure out when and how best to use phenotypic screening in drug discovery.
PDF
Pioneering biased ligand offers efficacy with reduced on-target toxicity
Katie Kingwell
p809 | doi:10.1038/nrd4784
Clinical success with Trevena's 'biased' G protein-coupled receptor ligand highlights the potential of exploring the nuances of receptor pharmacology.
PDF
NEWS IN BRIEF
Regulators approve the first cancer-killing virus
Asher Mullard
p811 | doi:10.1038/nrd4805
PDF
Priority review voucher pitfalls
Asher Mullard
p811 | doi:10.1038/nrd4806
PDF
FDA approves anticoagulant antidote
Asher Mullard
p811 | doi:10.1038/nrd4807
PDF
BIOBUSINESS BRIEFS
Market watch: Where is personalized medicine in industry heading?
Christopher-Paul Milne, Joshua P. Cohen & Ranjana Chakravarthy
p812 | doi:10.1038/nrd4759
PDF
BIOBUSINESS BRIEFS
Patent watch: Australia's highest court decides isolated nucleic acids are not patent eligible
Leigh Guerin & Mark Wickham
p813 | doi:10.1038/nrd4790
PDF
AN AUDIENCE WITH
Karen Midthun
p814 | doi:10.1038/nrd4792
Karen Midthun, outgoing Director of the FDA's Center for Biologics Evaluation and Research, reflects on 22 years at the agency.
PDF
FROM THE ANALYST'S COUCH
Two decades of new drug development for central nervous system disorders
Aaron S. Kesselheim, Thomas J. Hwang & Jessica M. Franklin
p815 | doi:10.1038/nrd4793
This article analyses the characteristics of the pipeline for experimental drugs for central nervous system disorders and how they have fared in the clinical phases prior to FDA approval over the past two decades.
PDF
RESEARCH HIGHLIGHTS
Top

Lead identification: Shedding light on dark chemical matter
p817 | doi:10.1038/nrd4787
PDF


Pain: TLR5 opens the door to neuropathic-pain treatment
p818 | doi:10.1038/nrd4785
PDF


Cancer: Xenograft encyclopaedia identifies drug combination opportunities
p818 | doi:10.1038/nrd4788
PDF


Immunotherapy: Remote control CARs
p819 | doi:10.1038/nrd4789
PDF


Infectious disease: Glutamine analogue reverses cerebral malaria
p820 | doi:10.1038/nrd4786
PDF



IN BRIEF

Cancer: Novel IDH1 mutant inhibitors identified | Inflammatory disorders: Blocking periodontal bone loss | Ophthalmology: Dual VEGF receptor antagonist reverses retinal disease | Drug screening: Identifying novel protein kinase inhibitors
PDF

Drug Discovery
JOBS of the week
Postdoctoral Position in Scaffold Design & Drug / gene Delivery for Neural Tissue Engineering Research
Nanyang Technological University (NTU)
Call for New Group Leaders
Institute of Molecular & Cellular Pharmacology (IPMC)
Postdoctoral Position in Neuroscience and Nanotechnology Northwestern University
Northwestern University
Call for new group leaders
The Institute of Molecular & Cellular Pharmacology (IPMC)
Lab Head, Immunology and Biochemistry
Novartis Institutes for BioMedical Research
More Science jobs from
Drug Discovery
EVENT
International Conference on Dermal Drug Delivery by Nanocarriers
14.03.16
Berlin, Germany
More science events from
Advertisement
Renova Life Inc. specializes in transgenic rabbits and guinea pigs production via conventional DNA or RNA microinjection, engaged in developing bioreactor systems and/or novel disease models with TELAN and CRISPR-Cas9 editing technologies.

For more information, please see
http://www.renovalife.com/transgenic_rabbits.php
http://www.renovalife.com/gene%20editing.php

 
PERSPECTIVES
Top
OPINION
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
David Brown
p821 | doi:10.1038/nrd4675
Drug resistance is threatening to sideline the currently available antibiotics, and new antibiotics are unlikely to become available before the current arsenal becomes ineffective. Brown proposes the use of approved drugs or neutraceuticals as antibiotic resistance breakers — compounds that could be administered alongside current antibiotics to prolong their useful lifespan — to bridge the gap.
Abstract | Full Text | PDF

OPINION
Pioneering government-sponsored drug repositioning collaborations: progress and learning
Donald E. Frail, Madeleine Brady, K. Jane Escott, Alison Holt, Hitesh J. Sanganee, Menelas N. Pangalos, Chris Watkins & Craig D. Wegner
p833 | doi:10.1038/nrd4707
A new model for translational research and drug repositioning has recently been established based on three-way partnerships between public funders, the pharmaceutical industry and academic investigators. This article discusses the progress with two pioneering initiatives — one involving the UK Medical Research Council and one involving the US National Center for Advancing Translational Sciences — and the unique requirements and challenges for this model.
Abstract | Full Text | PDF | Supplementary information

 
REVIEWS
Top
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Jonathan E. Zuckerman & Mark E. Davis
p843 | doi:10.1038/nrd4685
Several Phase I trials evaluating systemically administered siRNA-based therapeutics for cancer have recently been completed. Here, Zuckerman and Davis critically assess these studies and discuss key lessons learnt and implications for the future development of siRNA-based therapeutics and clinical trial design.
Abstract | Full Text | PDF

Complement, a target for therapy in inflammatory and degenerative diseases
B. Paul Morgan & Claire L. Harris
p857 | doi:10.1038/nrd4657
The complement cascade, a key regulator of innate immunity, is a rich source of potential therapeutic targets for diseases including autoimmune, inflammatory and degenerative disorders. Morgan and Harris discuss the progress made in modulating the complement system and the existing challenges, including dosing, localization of the drug to the target and how to interfere with protein–protein interactions.
Abstract | Full Text | PDF

Corrigendum: Cancer drug developers counteract kinase gatekeeper mutations
Asher Mullard
p877 | doi:10.1038/nrd4797
Full Text | PDF
Corrigendum: Do you want chips with that?
Asher Mullard
p877 | doi:10.1038/nrd4808
Full Text | PDF
Advertisement
Nature Outlook Cannabis

Cannabis is undergoing a resurgence of botanical and biomedical interest, spurred by claims of its therapeutic benefits. Yet research into these claims lags behind the legislation that allows medical marijuana use. Scientists are racing to fill this cannabis knowledge gap. 

Access the Outlook free online 

Produced with support from: GW Pharmaceuticals Plc.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments:

Post a Comment

Keep a civil tongue.

Label Cloud

Technology (1464) News (793) Military (646) Microsoft (542) Business (487) Software (394) Developer (382) Music (360) Books (357) Audio (316) Government (308) Security (300) Love (262) Apple (242) Storage (236) Dungeons and Dragons (228) Funny (209) Google (194) Cooking (187) Yahoo (186) Mobile (179) Adobe (177) Wishlist (159) AMD (155) Education (151) Drugs (145) Astrology (139) Local (137) Art (134) Investing (127) Shopping (124) Hardware (120) Movies (119) Sports (109) Neatorama (94) Blogger (93) Christian (67) Mozilla (61) Dictionary (59) Science (59) Entertainment (50) Jewelry (50) Pharmacy (50) Weather (48) Video Games (44) Television (36) VoIP (25) meta (23) Holidays (14)

Popular Posts